Hypertension is a condition that prevails globally and is estimated to affect over one billion people. It occurs irrespective of income status but is more common with advancing age. Physical inactivity and increasing body weight are significant contributory factors to developing hypertension. On this, #WorldCOPDDay it is worth noting the correlation between COPD, hypertension and cardiovascular disease. One of the major causes of COPD is smoking and exposure to second hand smoke or airborne pollutants.

‘ The pathophysiology of elevated cardiovascular risk in patients with chronic lung diseases is multi factorial. The over activity of the sympathetic nervous system due to systemic inflammation, hypoxia, air pollution, lower baroreflex sensitivity, inhibition of pulmonary stretch receptors, lower activity of parasympathetic nervous system, and elevated muscle sympathetic nerve activity may play central roles with or without atherosclerosis, resulting in hypertension and elevated BP variability’ – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646156/

The dabl system, designed and developed in close collaboration with leading experts in blood pressure measurement and cardiology, is the gold standard for Clinical Trials worldwide.

We have proven experience in all aspects of ABPM Monitoring for Clinical Trials and our statisticians and technicians can provide consultative support from protocol development through to analysis of results, for Phase I-IV single and multi-site clinical trials.